Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Hormone receptor profiles in Syrian patients with breast cancer

Ayla Kouli • 13 Dec 2024
SABCS 2024
Breast Cancer

Ayla Kouli, Damascus University, Damascus, Syria, discusses the hormone receptor expression patterns in Syrian patients with breast cancer. Findings reveal that more than half of cases were HER2+ or triple-negative, suggesting poorer prognoses, and the majority were hormone receptor-positive (HR+)/HER2-. The study highlights the impact of Syria’s protracted war on healthcare infrastructure and cancer registry practices, emphasizing the need for improved data collection and targeted interventions to address breast cancer outcomes in this population. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals